Summary of Study ST002944
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001831. The data can be accessed directly via it's Project DOI: 10.21228/M81Q73 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002944 |
| Study Title | Longitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin |
| Study Type | (un)targeted MS |
| Study Summary | This study is part of a multi-part study, including a. longitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin b. polar fecal metabolomics of a patient cohort c. fecal lipidomics of a patient cohort d. polar urinary metabolomics of a patient cohort e. polar metabolomics of in vitro digestions This specific part is part a. longitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin |
| Institute | Ghent University |
| Department | Department of Translational Physiology, Infectiology and Public Health |
| Laboratory | Laboratory for Integrative Metabolomics |
| Last Name | De Paepe |
| First Name | Ellen |
| Address | Salisburylaan 133, 9820 Merelbeke, Belgium |
| Ellen.DePaepe@UGent.be | |
| Phone | 0032479081098 |
| Submit Date | 2023-07-06 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-11-01 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR003066 |
| Treatment Summary: | Two different mice strains and two different protocols were tested: BALB/c (BC) mice and C57Bl/6 (B6) mice. The first sensitization protocol was based on Adel-Patient et al., in which 4-week-old mice received oral gavages containing ß-lactoglobulin (BLG) and cholera toxin (CT) once a week for 6 weeks 20 (treatment W), the control groups received either BLG in PBS (X), CT in PBS (Y) or PBS alone (Z). The second protocol was adapted from Shindo et al. and included intragastrical administration of BLG in PBS or oil emulsion, followed by intraperitoneal injection of sodium salicylate (SA). The latter protocol was performed 5x a week for 3 weeks. Group A received BLG in PBS + SA, group B BLG in oil + SA, group C BLG in PBS + PBS, group D BLG in oil + PBS, group E and F were vehicle controls with group E receiving PBS + SA, and group F oil + SA |
| Treatment Compound: | Beta-lactoglobulin, cholera toxin |
| Treatment Route: | oral gavage, intraperitoneal injection |
| Treatment Dose: | 1 mg ß-lactoglobulin (BLG) per g body weight mixed with 10 µg of cholera toxin (CT) in 0.1 mL PBS, or 1 mg BLG in 0.1 mL individual antigen solution (vehicle), which was either PBS or an oil emulsion (saline, linoleic acid, and lecithin at 5:4:1 by volume). Intraperitoneal administration of 0.1 mL PBS or PBS containing 0.2 mg sodium salicylate (SA) |
| Treatment Doseduration: | 3 or 7 weeks |
| Treatment Vehicle: | PBS or oil emulsion |
| Animal Anesthesia: | CO |
| Animal Fasting: | Evening before antigen challenge |
| Animal Endp Euthanasia: | cervical dislocation |
| Animal Endp Clinical Signs: | severe anaphylaxis |
